Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SanBio Co ( (JP:4592) ) has issued an update.
SanBio Co., Ltd. has successfully completed the third commercial production run of AKUUGO Suspension for Intracranial Implantation, meeting the necessary approval conditions for shipment. The company plans to file a partial change application and expects to begin shipments in the second quarter of the fiscal year ending January 31, 2026. This development is anticipated to have minimal impact on the current fiscal year’s financial performance.
The most recent analyst rating on (JP:4592) stock is a Hold with a Yen1400.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Co., Ltd., founded in California in 2001, is a company focused on regenerative medicine. It engages in the research, development, manufacture, and sale of regenerative cell medicines. The company aims to be a global leader in this field and has received conditional approval for its main product, AKUUGO, which is used to improve chronic motor paralysis associated with traumatic brain injury.
Average Trading Volume: 4,988,822
Technical Sentiment Signal: Buy
Current Market Cap: Yen231.9B
For detailed information about 4592 stock, go to TipRanks’ Stock Analysis page.